Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Topotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 18/20 | 0.97 |
| ▸ | MEN1 | O00255 | 5/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.97 |
| ▸ | CASP1 | P29466 | 3/20 | 0.97 |
| ▸ | CASP7 | P55210 | 3/20 | 0.97 |
| ▸ | HBB | P68871 | 3/20 | 0.97 |
| ▸ | MAPT | P10636 | 3/20 | 0.97 |
| ▸ | USP2 | O75604 | 2/20 | 0.97 |
| ▸ | LMNA | P02545 | 2/20 | 0.97 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.97 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.97 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.97 |
| ▸ | TOP2A | P11388 | 1/20 | 0.97 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.97 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Topotecan SCHEMBL29726458 | 0.98 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL30712226 | 0.98 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL3836 | 0.98 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL14577671 | 0.98 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL9971346 | 0.98 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL3927536 | 0.98 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL5531617 | 0.98 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL29350221 | 0.98 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL31517322 | 0.98 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL10588295 | 0.98 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190015423-A1 | REGULATION OF GENE EXPRESSION BY MODULATING PRIMARY CILIA LENGTH | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-01-17 | — | — | US | claimed |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250228937-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | TORAY INDUSTRIES, INC. (JP) | 2025-07-17 | — | — | US | disclosed |
| WO-2025123318-A1 | TETRACYCLIC DERIVATIVES AS K-Ras G12D INHIBITORS | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025124415-A1 | TETRACYCLIC DERIVATIVES AS K-Ras G12D INHIBITORS | NIKANG THERAPEUTICS INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025085880-A1 | PROTEOMICS PROCESSING AND PATIENT STRATIFICATION | YATIRIBIO, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2024234360-A1 | TETRACYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS , INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| WO-2024197503-A1 | TRICYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS , INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| US-20240287100-A1 | ALKYLIDENE DERIVATIVES AS KRAS INHIBITORS | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | disclosed |
| CN-102065897-B | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response | PHARNEXT | 2013-11-13 | — | — | CN | disclosed |
| US-8552041-B2 | Therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response | PHARNEXT (FR) | 2013-10-08 | — | — | US | disclosed |
| EP-2282779-B1 | NEW THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE AND RELATED DISORDERS THROUGH A MODULATION OF CELL STRESS RESPONSE | PHARNEXT (FR) | 2013-03-13 | — | — | EP | disclosed |
| US-20120071483-A1 | THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE AND RELATED DISORDERS THROUGH A MODULATION OF CELL STRESS RESPONSE | PHARNEXT (FR) | 2012-03-22 | — | — | US | disclosed |
| US-20120058992-A1 | THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE AND RELATED DISORDERS THROUGH A MODULATION OF ANGIOGENESIS | PHARNEXT (FR) | 2012-03-08 | — | — | US | disclosed |
| US-20110269764-A1 | THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE AND RELATED DISORDERS THROUGH A MODULATION OF SYNAPSE FUNCTION | PHARNEXT (FR) | 2011-11-03 | — | — | US | disclosed |
| CN-102065858-A | Combination compositions for treating alzheimer's disease and related conditions using zonisamide and acamprosate | PHARNEXT | 2011-05-18 | — | — | CN | disclosed |
| CN-102065898-A | Novel therapeutic approaches for treating alzheimer's disease and related disorders by modulating angiogenesis | PHARNEXT | 2011-05-18 | — | — | CN | disclosed |
| CN-102065897-A | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response | PHARNEXT | 2011-05-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | TOP1 832/4885MEN1 4544/4885KMT2A 1780/4885 |
| US-20240287100-A1 | ALKYLIDENE DERIVATIVES AS KRAS INHIBITORS | KRAS, NRAS, HRAS | TOP1 2946/4885MEN1 1995/4885KMT2A 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.